Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001780469 | SCV002016990 | pathogenic | not provided | 2019-06-18 | criteria provided, single submitter | clinical testing | |
Medical Genetics UMG, |
RCV002300590 | SCV002587811 | pathogenic | Congenital hypotrichosis with juvenile macular dystrophy | criteria provided, single submitter | clinical testing | The c.160+1G>A variant results from a G to A substitution in intron 2 of the CDH3 gene, affecting a donor splice site. This splicing variant is predicted to cause a loss of function. The frequency of this variant in gnomAD database is 0.00001394. In our laboratory this variant was found in trans with a pathogenic variant in a patient affected by congenital hypotrichosis with juvenile macular dystrophy (HJMD). | |
Labcorp Genetics |
RCV001780469 | SCV003443657 | pathogenic | not provided | 2024-01-03 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 2 of the CDH3 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CDH3 are known to be pathogenic (PMID: 15805154, 27386845, 29620724). This variant is present in population databases (no rsID available, gnomAD 0.004%). Disruption of this splice site has been observed in individuals with hypotrichosis and juvenile macular dystrophy (PMID: 17342797, 31696509). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 1322049). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Institute of Human Genetics, |
RCV004815631 | SCV005069829 | pathogenic | Retinal dystrophy | 2019-01-01 | criteria provided, single submitter | clinical testing |